AbbVie Partner Short - An open-label prospective study of the real-life use of OnabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
226 Aufrufe
Doctupus Tutorials
Inhalt
An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study
[1]
Fayyaz Ahmed et al., The Journal of Headache and Pain (2019) 20:26